Furthermore, in the subset of see more patients with an eGFR pre-cART ≥90 mL/min per 1.73 m2, the time of a confirmed eGFR reduction from pre-cART levels was alternatively

defined as the date of the first of two consecutive eGFR values <90 mL/min per 1.73 m2. Poisson regression analyses including the same variables as were included in the main analysis were employed to identify independent predictors of a reduction of eGFR. Patients included in the analysis (n=1505) showed significant differences in immunovirological variables compared with excluded patients (n=5762; Table 1); included patients had higher CD4 cell counts (505 vs. 450 cells/μL, respectively; P<0.0001) and higher median HIV RNA levels (4.14 vs. 3.00 log10 HIV-1 RNA copies/mL, respectively; P<0.0001) at baseline. Included patients were younger (38 vs. 39 years, respectively; P<0.0001) and more likely

to be affected by diabetes and/or hypertension (2%vs. 1%, respectively; P=0.02); a lower percentage of included patients acquired HIV infection thorough injecting drug use (29% of the included patients vs. 35% of the excluded patients). There were no clinical differences in the percentage of female patients or CD8 cell count. A total of 1505 patients satisfied the inclusion criteria for the cross-sectional analysis. The clinical and immunovirologic characteristics of the patients, stratified by eGFR at baseline Vemurafenib clinical trial (<90 or ≥90 mL/min/1.73 m2), are summarized in Table 2. A

confirmed eGFR<90 mL/min/1.73 m2 was observed in 363 (24%) of the patients. Of these, 353 (97%) had an eGFR in the range of 60–89 mL/min/1.73 m2, while only 10 patients Chlormezanone (3%) had an eGFR of 30–59 mL/min/1.73 m2 and none had an eGFR below 30 mL/min/1.73 m2. In univariable analysis, compared with patients with normal eGFR, patients with a value of eGFR<90 mL/min/1.73 m2 at baseline were older, had higher CD4 cell counts, and were more likely to be female and to have suffered from diabetes and/or hypertension prior to baseline; in contrast, patients with normal eGFR were more likely to be coinfected with hepatitis B or C virus (Table 2). After adjustment, older age [odds ratio (OR) 1.58 per 10 years older; 95% confidence interval (CI) 1.37–1.82], female gender (OR 2.41 vs. male; 95% CI 1.75–3.31), a prior history of diabetes and/or hypertension (OR 2.36 vs. neither; 95% CI 1.08–5.14), baseline CD4 count (OR 1.06 per 100 cells/μL higher; 95% CI 1.01–1.11) and hepatitis coinfection (OR 0.51 vs. HIV monoinfection; 95% CI 0.34–0.78) were the sole independent predictors of a value<90 mL/min/1.73 m2 at baseline (Table 2). A total of 644 patients (43% of the total studied) started cART at some point during follow-up and were included in the longitudinal analysis (Table 3). The median calendar year of cART initiation was 2005 (range 2000–2009) and the median number of creatinine values post cART was 6 [interquartile range (IQR) 2–10].